* DO NOT QUOTE OR DISTRIBUTE WITHOUT PERMISSION * Immunoglobulin (Ig) Concentrations in Blood (micrograms/milliliter obtained by ELISA method) Assay Genotype Drug ID time0 15days 1m 2m 3m 4m 5m 6m IgG-1 patients active 0100 300.8 215.1 300.8 202.3 333.1 1546 12326 4994 IgG-1 patients active 0200 221.6 1208 2301 4669 9755 16852 12628 17898 IgG-1 patients active 0300 789.8 1649 3119 3340 8068 5376 . . IgG-1 patients active 0400 0.764 1352 749.7 6734 8825 12500 . . IgG-1 patients active 0500 1 1.097 11.82 308.7 403.1 2762 . . IgG-1 patients active 0600 3.092 6.217 5.326 9.344 947.7 14976 . . IgG-1 patients active 1013 13727 11808 9251 8885 11808 16300 19654 . IgG-1 patients active 1014 2.49 8.225 512.1 139.9 917.8 2762 7301 . IgG-1 patients active 1016 215.1 71.29 636.3 8470 11954 21639 19914 . IgG-1 patients active 1017 3.764 6.217 8011 11808 11881 11591 11600 . IgG-1 patients active 1018 3504 2175 7788 10410 23116 16759 12660 . IgG-1 patients active 1019 1678 257.7 191.7 1544 6405 2223 6024 . IgG-1 patients active 1020 986.3 823.5 1544 1056 1802 1899 3439 . IgG-1 patients active 1021 13366 8592 12350 6502 97 12731 9993 . IgG-1 patients active 1022 45.56 1128 2774 3022 7070 8941 . . IgG-1 patients active 1023 139.9 128.3 3416 1044 1693 4496 5777 . IgG-1 patients active 1024 4262 6535 10501 8289 10372 13465 10501 . IgG-1 patients placebo 1001 252.3 1056 3911 5807 5477 7278 6437 . IgG-1 patients placebo 1002 12069 9138 8214 7810 6149 7488 5961 . IgG-1 patients placebo 1003 4931 5900 8824 7002 9662 8516 7174 . IgG-1 patients placebo 1004 394 3671 6634 7523 12973 8863 9865 . IgG-1 patients placebo 1006 12453 9297 15378 15648 17154 19292 19913 . IgG-1 patients placebo 1007 553.4 580.7 1070 27428 25437 21424 22498 . IgG-1 patients placebo 1008 2483 8109 27428 32457 25977 23545 24767 . IgG-1 patients placebo 1009 1016 1406 1585 2381 2822 3528 3876 . IgG-1 controls active 2001 178.4 186.3 560.2 1392 3013 4547 5146 . IgG-1 controls active 2002 389.2 400.3 507.6 1284 1700 2916 4730 . IgG-1 controls active 2003 405.9 232.4 464.2 1324 1683 2381 5602 . IgG-1 controls active 2004 311.2 232.4 623.2 1493 1862 1493 5401 . IgG-1 controls active 2005 1770 667.8 495 823.7 1825 5321 5602 . IgG-1 controls active 2006 394.8 321.1 1197 1126 2646 3081 5344 . IgG-1 controls active 1000 647.3 521.2 1063 2161 2858 1953 2076 2034 IgG-1 controls active 2000 596.4 604.9 1663 1785 4367 8869 4549 6065 IgG-1 controls active 3000 1500 830.5 1242 2496 1557 1500 1627 . IgG-1 controls active 4000 512.9 588 1993 2680 2990 7477 8235 7675 IgG-1 controls active 5000 750.9 903 1455 2323 2034 1798 1500 2970 IgG-1 controls active 6000 664.3 604.9 6769 10198 4612 3925 3823 4309 IgG-1 controls placebo 2007 3448 771.8 616 771.8 546.7 887.5 2264 . IgG-1 controls placebo 2008 501.3 527 464.2 1350 1806 2457 6340 . IgG-1 controls placebo 2009 884.7 742.1 707.3 903 1615 1748 1604 . IgG-1 controls placebo 2010 373.1 1379 256 579.6 342 473 830.5 . IgG-1 controls placebo 2011 422.3 884.7 1111 1121 1242 921.4 724.7 . IgG-1 controls placebo 2012 638.7 930.6 1072 1201 930.6 1357 1836 . Immunoglobulin (Ig) Concentrations in Blood (micrograms/milliliter obtained by ELISA method) Assay Genotype Drug ID time0 15days 1m 2m 3m 4m 5m 6m IgG2a patients active 0100 3779 895.2 770 547.3 263.3 241.7 860.6 434.9 IgG2a patients active 0200 200.3 82.57 118.8 308.1 370.6 563.2 71.74 1425 IgG2a patients active 0300 2427 1656 817.1 712.9 1025 754.4 . . IgG2a patients active 0400 26.6 137.6 257 217.7 644.9 909.7 . . IgG2a patients active 0500 8.376 25 32 43 83.68 244.7 . . IgG2a patients active 0600 14.71 34 25 32 197.4 407.7 . . IgG2a patients active 1013 496.7 91.55 123.7 241.7 547.3 514 512 . IgG2a patients active 1014 241.7 785.5 1470 2060 1154 1232 909.1 . IgG2a patients active 1016 734.7 188.9 475.8 814.8 1334 1431 1172 . IgG2a patients active 1017 427.6 22.68 569.2 1020 936.9 881.3 1172 . IgG2a patients active 1018 1916 1311 3259 1958 3369 3875 3150 . IgG2a patients active 1019 21499 15854 13364 8354 17244 6397 5467 . IgG2a patients active 1020 2492 1233 293 570.9 1310 936 1587 . IgG2a patients active 1021 936 758.8 919.2 2274 1084 486 524.4 . IgG2a patients active 1022 12.34 1773 7172 9722 7279 4993 . . IgG2a patients active 1023 31.4 10 550.8 498.6 235.3 401.3 3473 . IgG2a patients active 1024 179.2 253.9 1597 2162 3785 2572 5324 . IgG2a patients placebo 1001 1130 1451 1075 919.2 640.4 1252 902.5 . IgG2a patients placebo 1002 1899 910.9 1350 505 116.1 395.6 171.1 . IgG2a patients placebo 1003 57.67 41.5 50.46 103 103 221.8 407.2 . IgG2a patients placebo 1004 39 221.8 524.4 413 195.7 115 25 . IgG2a patients placebo 1006 155.6 454.9 378.5 813.3 698.4 919.2 1066 . IgG2a patients placebo 1007 1311 1464 1116 1618 1763 1641 2468 . IgG2a patients placebo 1008 608.7 584.2 214.1 397.8 454.7 570.5 680.5 . IgG2a patients placebo 1009 1353 1754 1692 3179 2474 3674 12978 . IgG2a controls active 2001 111.1 35 369.2 1778 1870 3435 13425 . IgG2a controls active 2002 202.4 240.4 162.5 1142 1169 2458 5691 . IgG2a controls active 2003 24 56 287.7 1452 1030 1328 2672 . IgG2a controls active 2004 227.5 153.5 717 1134 1008 1200 1990 . IgG2a controls active 2005 67.39 330.2 219.9 948.2 1116 1472 3331 . IgG2a controls active 2006 275.8 330.2 913 1628 1484 2163 12612 . IgG2a controls active 1000 56 45 260.4 1603 2385 3311 4696 4852 IgG2a controls active 2000 249.6 185.4 388.8 1436 1825 9538 10128 6648 IgG2a controls active 3000 101.8 170.2 111.8 1541 1961 2758 4049 . IgG2a controls active 4000 157.1 74 569 1447 1681 3536 2435 1835 IgG2a controls active 5000 126.7 74.85 272.4 1195 1500 2723 2416 1697 IgG2a controls active 6000 171.8 168.6 1309 1432 1532 4866 2618 4797 IgG2a controls placebo 2007 155.8 366.1 320.6 512.5 312.5 627.7 721 . IgG2a controls placebo 2008 75 105.5 95 188.2 263.7 454.7 373.7 . IgG2a controls placebo 2009 172.1 354.5 392.6 469.3 1144 1571 1064 . IgG2a controls placebo 2010 85.38 1070 679.5 344.9 390.7 511.9 491.6 . IgG2a controls placebo 2011 229.9 443.2 990.1 1070 787 635.2 714.6 . IgG2a controls placebo 2012 274.3 321.7 426.4 469.3 180.9 400.1 535.9 . Immunoglobulin (Ig) Concentrations in Blood (micrograms/milliliter obtained by ELISA method) Assay Genotype Drug ID time0 15days 1m 2m 3m 4m 5m 6m IgG2b patients active 0100 25.28 50.96 76.83 30.99 32.18 122 510.2 322.2 IgG2b patients active 0200 12.02 7.632 12.02 6.982 46.63 166.1 119.8 113.4 IgG2b patients active 0300 12.83 146.8 186.6 91.47 248.5 20.08 . . IgG2b patients active 0400 5 29.81 13.66 6.982 50.96 80.38 . . IgG2b patients active 0500 3.5 2.684 2.684 5.178 38.47 80.38 . . IgG2b patients active 0600 1 1 1.196 2.267 176.2 197.2 . . IgG2b patients active 1013 9.003 0.421 24.2 5.755 24.2 32.18 87.71 . IgG2b patients active 1014 15.39 22.1 580.9 567.3 1808 2849 1430 . IgG2b patients active 1016 97.26 61.71 63.32 285.8 676.1 816.7 329 . IgG2b patients active 1017 101.2 25.28 146.8 197.2 213.7 2465 1834 . IgG2b patients active 1018 149.1 124.1 401.3 666.2 1064 822.1 416.6 . IgG2b patients active 1019 1864 677.5 327.9 506.1 696.7 524.9 482.5 . IgG2b patients active 1020 199.2 97.33 96.06 78.9 199.2 125.4 273.3 . IgG2b patients active 1021 128.2 76.55 173.1 202.6 23 52.27 38.45 . IgG2b patients active 1022 81.28 818.9 315.3 91.04 243.1 102.5 . . IgG2b patients active 1023 55.41 56.46 362.5 168.3 200.9 76.55 241.3 . IgG2b patients active 1024 141.1 115.7 321.6 866.4 420.2 355.9 325.8 . IgG2b patients placebo 1001 586.6 756.2 327.9 145.5 151.5 99.88 156 . IgG2b patients placebo 1002 62.93 69.63 53.31 41.3 26.83 61.84 50.22 . IgG2b patients placebo 1003 83.68 51.24 67.37 57.52 69.63 82.48 82.48 . IgG2b patients placebo 1004 184.3 209.4 157.5 101.2 49.2 46.19 . . IgG2b patients placebo 1006 50.22 47.19 57.52 57.52 81.28 86.11 65.14 . IgG2b patients placebo 1007 189.2 189.2 44.52 89.13 93.46 100.9 97 . IgG2b patients placebo 1008 59.79 94.93 12.59 146.4 122.8 162.6 143 . IgG2b patients placebo 1009 146.4 110 92.01 311.9 181.4 195.1 179 . IgG2b controls active 2001 71.26 40.14 110 294.6 409.5 738.2 976 . IgG2b controls active 2002 179.5 213.4 75.25 645.4 292.2 1057 654 . IgG2b controls active 2003 16.48 59.79 157.1 700.9 592.8 725.6 698 . IgG2b controls active 2004 160.8 58.56 119.5 275.4 205.2 92.01 103 . IgG2b controls active 2005 96.4 59.79 151.7 234.7 467.2 1142 1089 . IgG2b controls active 2006 175.7 155.3 245.7 808 1225 1472 1245 . IgG2b controls active 1000 41.46 26.1 120.1 276.2 243.2 276.2 710.1 535.9 IgG2b controls active 2000 24.17 81.33 198.4 620.9 450.4 4245 3652 2661 IgG2b controls active 3000 127.3 58.25 164.7 819.5 651.7 505.7 876.3 . IgG2b controls active 4000 29.04 30.04 136 462.2 777.7 716.1 928.6 445.8 IgG2b controls active 5000 31.04 45.8 206.8 299.1 409.4 556.5 593.6 918 IgG2b controls active 6000 30.04 50.25 385.2 525.7 580.2 618.1 686.4 677.6 IgG2b controls placebo 2007 102.4 64.8 52.54 93.46 110 195.1 210 . IgG2b controls placebo 2008 32.86 56.12 27.01 76.6 287.3 515.9 654 . IgG2b controls placebo 2009 75.07 68.94 53.64 52.5 243.2 343 153.9 . IgG2b controls placebo 2010 27.07 186.9 17 66.52 5 4 149.3 . IgG2b controls placebo 2011 57.09 124.4 167.8 174.1 246.8 104.9 131.6 . IgG2b controls placebo 2012 34.1 89.01 123 61.76 30.04 40.39 49.13 . Immunoglobulin (Ig) Concentrations in Blood (micrograms/milliliter obtained by ELISA method) Assay Genotype Drug ID time0 15days 1m 2m 3m 4m 5m 6m IgG-3 patients active 0100 1734 1524 1256 1394 1060 742.1 1661 1109 IgG-3 patients active 0200 953 964.9 1398 4364 7316 6252 4920 6747 IgG-3 patients active 0300 1441 1989 2641 2818 2063 1214 . . IgG-3 patients active 0400 338.4 660.7 1599 2589 1550 1441 . . IgG-3 patients active 0500 458.3 552.2 567.7 796.4 606.5 450.4 . . IgG-3 patients active 0600 831.5 941.2 1252 1794 6840 2358 . . IgG-3 patients active 1013 1121 637.5 1285 2505 1827 1497 1310 . IgG-3 patients active 1014 1675 2103 2267 4037 9274 23456 7016 . IgG-3 patients active 1016 2019 1335 909.7 1301 2567 5206 24987 . IgG-3 patients active 1017 1893 1214 1497 2210 1001 1343 1331 . IgG-3 patients active 1018 2723 2516 2758 1999 2336 1702 1235 . IgG-3 patients active 1019 1393 1031 991.1 2221 2051 983.8 914.1 . IgG-3 patients active 1020 2297 2184 1157 1396 1829 1668 1325 . IgG-3 patients active 1021 1562 1837 2091 2615 2315 1610 1867 . IgG-3 patients active 1022 1898 2876 2579 1635 1378 1289 . . IgG-3 patients active 1023 1522 2801 7894 2643 1739 1310 1146 . IgG-3 patients active 1024 2075 1871 2816 2801 2457 1788 1403 . IgG-3 patients placebo 1001 1964 1898 1639 1676 1844 2023 1497 . IgG-3 patients placebo 1002 4468 5030 5892 3601 1375 2201 1339 . IgG-3 patients placebo 1003 3328 1883 2213 2639 2209 1913 1475 . IgG-3 patients placebo 1004 3153 2339 2796 2055 1257 1020 . . IgG-3 patients placebo 1006 1944 1780 1913 1679 1421 1537 1117 . IgG-3 patients placebo 1007 3260 3341 2582 2732 2732 1954 2345 . IgG-3 patients placebo 1008 1151 1211 882 1350 1293 1172 1439 . IgG-3 patients placebo 1009 2003 2196 1363 1666 788.8 1138 1178 . IgG-3 controls active 2001 1376 1557 1848 2083 1198 1535 1398 . IgG-3 controls active 2002 1535 1939 829 2013 1398 2677 3144 . IgG-3 controls active 2003 1147 1315 1125 1437 1039 1086 1155 . IgG-3 controls active 2004 1151 1499 1407 1451 969.4 877.6 765 . IgG-3 controls active 2005 1354 1680 1460 1350 2003 1857 2003 . IgG-3 controls active 2006 1341 1468 1289 1974 1332 1272 1078 . IgG-3 controls active 1000 530.7 891 1082 966 986.9 960 1274 1120 IgG-3 controls active 2000 390.9 1005 912.1 1132 1165 1793 1512 1573 IgG-3 controls active 3000 1388 641.6 1020 1251 1123 768.7 759.3 . IgG-3 controls active 4000 578.6 805.7 1168 1182 1046 1265 1494 1349 IgG-3 controls active 5000 425.7 930.1 1439 1601 1433 1135 1034 1153 IgG-3 controls active 6000 481.1 900 1539 1530 1373 1427 1209 1182 IgG-3 controls placebo 2007 1853 1671 1580 2400 1437 1630 1548 . IgG-3 controls placebo 2008 1954 1988 1625 2286 2238 2641 2588 . IgG-3 controls placebo 2009 954 1108 1385 1251 1941 2360 1153 . IgG-3 controls placebo 2010 909 1928 1566 1058 1122 1364 1150 . IgG-3 controls placebo 2011 1406 1298 1515 1415 1159 1212 1123 . IgG-3 controls placebo 2012 839.4 995.8 1159 1028 746.8 972 1394 . Immunoglobulin (Ig) Concentrations in Blood (micrograms/milliliter obtained by ELISA method) Assay Genotype Drug ID time0 15days 1m 2m 3m 4m 5m 6m IgM patients active 0100 1031 510.9 445.6 708.5 642.9 734.8 2702 5485 IgM patients active 0200 510.9 565.2 591.6 421.6 507.9 484.4 377 1204 IgM patients active 0300 416 531.7 563.6 747.2 899.1 583.8 . . IgM patients active 0400 586.9 1185 772.6 713.7 1036 633.1 . . IgM patients active 0500 533.2 710.2 552.9 605.8 659.3 838.9 . . IgM patients active 0600 639.6 487.4 956.4 478.6 833 781.9 . . IgM patients active 1013 533.2 427.2 427.2 403.4 749 664.3 . . IgM patients active 1014 800.5 656 654.4 783.7 601 749 . . IgM patients active 1016 1092 577.5 601 604.2 557.5 752.6 . . IgM patients active 1017 1145 785.6 852.6 701.6 662.7 842.8 . . IgM patients active 1018 3718 1331 1791 1008 583.8 664.3 . . IgM patients active 1019 1901 2547 1458 1492 1069 1094 . . IgM patients active 1020 1600 1351 843 566 744.7 1057 . . IgM patients active 1021 971.6 1142 785.7 679.2 657 1157 . . IgM patients active 1022 917.4 1823 1619 890.7 747.2 747 . . IgM patients active 1023 809 1773 1905 988 885.3 1049 . . IgM patients active 1024 1035 1183 1723 843 888 1259 . . IgM patients placebo 1001 1357 1700 925.5 732 632.3 1119 . . IgM patients placebo 1002 775.4 578.9 576.5 538.4 414 524.3 . . IgM patients placebo 1003 2165 1066 719.3 719.3 979.8 861.5 . . IgM patients placebo 1004 2937 1085 898.7 652 765.1 734.5 . . IgM patients placebo 1006 1684 757.5 814.2 1400 1046 1867 . . IgM patients placebo 1007 1208 804.3 742.5 771.7 798.3 840.4 . . IgM patients placebo 1008 1442 765.8 360.9 613.3 487.9 621.5 . . IgM patients placebo 1009 964.8 765.8 492.9 783.5 565.1 416.8 . . IgM controls active 2001 742.5 1868 1119 1595 1665 1956 . . IgM controls active 2002 987.2 2263 1076 1591 1461 1673 . . IgM controls active 2003 643.4 1096 952.1 849.5 819.2 1036 . . IgM controls active 2004 1056 1307 1076 870.9 1390 867.8 . . IgM controls active 2005 1952 1003 971.2 1618 1579 2020 . . IgM controls active 2006 911.1 1587 1059 1394 1885 1332 . . IgM controls active 1000 942.6 1371 792.7 607.5 811.3 704.1 1062 924.7 IgM controls active 2000 436.2 1165 638.1 455 856.6 776.1 741.6 693.5 IgM controls active 3000 1054 993.3 556 732.6 960.7 644.9 594.1 . IgM controls active 4000 830 1614 1031 1056 1088 1043 1152 1686 IgM controls active 5000 816.9 1145 841.4 1293 1101 942.6 1014 1559 IgM controls active 6000 1473 1537 1077 972.9 1136 1222 1343 1654 IgM controls placebo 2007 2485 610.6 804.3 1126 1109 1023 . . IgM controls placebo 2008 901.8 1170 710.8 1003 768.7 1918 . . IgM controls placebo 2009 946.6 877.8 1014 763.3 1500 1450 . . IgM controls placebo 2010 759.7 1521 675 526.6 497 1233 . . IgM controls placebo 2011 643.2 752.4 650.1 754.2 451.8 515.3 . . IgM controls placebo 2012 651.8 936.7 491.3 455 380.9 607.5 . .